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Background: Pneumococcal immunization is recommended in children with cystic ﬁbrosis (CF). To date, however, there are no published studies
on the efﬁcacy of pneumococcal vaccination in this group of patients.
Methods: We carried out a retrospective study of serotype-speciﬁc pneumococcal antibody responses to immunization with Prevenar 7 and
Pneumovax II in a cohort of children with CF.
Results: Nine children had been immunized with Prevenar 7, and all had serotype-speciﬁc pneumococcal antibody levels in the protective range
(N0.35 mg/L) to all 7 immunizing serotypes. In contrast, only 7 of 33 patients (21%) immunized with Pneumovax II made protective antibody
responses to all 7 serotypes, and 3 failed to make protective antibodies to any of the serotypes. Controlling for age as a confounder in the analysis,
children with impaired antibody responses to pneumococcal polysaccharide (Pneumovax II) immunization had lower Shwachman–Kulczycki
scores than children with normal polysaccharide antibody responses. All isolates of Pseudomonas aeruginosa occurred in patients with impaired
anti-pneumococcal antibody responses, and a broader range of respiratory pathogens was isolated from these children.
Conclusions: Impaired antibody responses to immunization with Pneumovax II are common in children with CF and this may be associated with
increased disease severity.
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Cystic fibrosis (CF) lung disease is characterized by a
progressive decline in lung function, due to recurrent exacerbations
of lower respiratory tract infections. Bacteria like Staphylococcus
aureus and Haemophilus influenzae cause most of the early
respiratory tract infections, before Pseudomonas aeruginosall rights reserved.
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pneumoniae is rarely isolated from CF sputum and therefore
its pathogenic role in CF is controversial. The prevalence of
S. pneumoniae in the CF respiratory tract may however be
underestimated, as the organism is difficult to isolate from sputa
often heavily infected with other organisms [4,5].
Pneumococcal immunization of patients with CF is recom-
mended by the European Cystic Fibrosis Society Vaccination
Group [5], the American Academy of Pediatrics [6], and the UK
Health Protection Agency [7]. Vaccination with polysaccharide
vaccines confers only transient immunity and revaccination has
been recommended by the European Cystic Fibrosis Society
Vaccination Group every 3–5 years in patients with a more rapid
decline in antibody titres and those of increased risk for invasive
disease [5]. However, there are no published studies on the
efficacy of pneumococcal vaccination in children or adults with
CF [8]. Impaired immunoglobulin production has been described
in a subgroup of children with CF [9–12]. It is important
therefore to establish whether children with CF mount normal
antibody responses to immunization against pneumococcus.
To evaluate the efficacy of pneumococcal vaccination, we
conducted a retrospective analysis of antibody responses to
vaccination in children with CF attending our CF centre.
2. Materials and methods
2.1. Subject population and study design
All of the children included in the study had a diagnosis of CF,
confirmed by sweat testing and/or the presence of two
disease-causing mutations in the CFTR gene. The data for this
retrospective, cross-sectional study were extracted from Univer-
sity Hospitals of Leicester NHS Trust databases. The data used
were obtained at an annual review between June 2009 and May
2010. The FEV1% predicted was assessed by standard spirometry
following ATS/ERS guidelines [13], and BMI-z scores were
calculated from height and weight values. The chest radiograph
Northern score [14] was assigned by a consultant paediatric
radiologist, and Shwachman–Kulczycki (S–K) scores (based on
a combination of scores for general activity, physical examina-
tion, nutrition, and chest radiograph findings) were calculated for
each child [15]. Clinicians assigning Northern scores and S–K
scores were blinded to the result of the pneumococcal antibody
responses to immunization. Airway microbiology was reviewed
for the 12 month study period. Review and anonymized use of
patient clinical data were approved by the East Midlands
Research Ethics Committee, reference number 12/WM/0285.
2.2. Pneumococcal antibody testing
Serotype-specific pneumococcal antibody titres were mea-
sured to the 7 serotypes of pneumococcus present in both
Prevenar 7 and Pneumovax II (serotypes 4, 6B, 9V, 14, 18C, 19F
and 23F), plus a further 6 serotypes included in Pneumovax II but
not Prevenar 7 (serotypes 1, 3, 5, 7F, 8 and 19A), using a
multiplex fluorescent bead assay (BioPlex Protein Array System,
BioRad Laboratories, Hercules, CA), as described by Willcockset al. [16]. The Food and Drug Administration (FDA) standard
reference serum (89SF) was used as calibrant in validating the
serotype-specific anti-pneumococcal antibody levels.
2.3. Pneumococcal vaccines and criteria used to assess
antibody responses
Two pneumococcal vaccines are available in the UK:
Pneumovax II, an unconjugated polysaccharide vaccine incor-
porating capsular polysaccharide from 23 pneumococcal
serotypes; and Prevenar, incorporating capsular polysaccharide
antigens from 7 serotypes (prior to 2010; 13 serotypes after
2010) conjugated to a protein carrier molecule (diphtheria
toxoid). Prevenar has been included in the childhood vaccina-
tion schedule in the UK since 2006. Serotype-specific
pneumococcal antibody levels N0.35 mg/L are considered by
the WHO to represent protection against invasive pneumococ-
cal infection [17]. In line with the recommendations for
pneumococcal immunization [5–7], we routinely measure
pneumococcal antibody levels at the CF annual review.
Where antibody levels are deemed inadequate, we recommend
booster immunization with Pneumovax II in children N2 years,
with post-immunization pneumococcal antibody testing four to
six weeks following the immunization. An adequate response
to immunization is taken as a post-immunization titre N1.3 mg/
L, in accordance with a recent American Academy of Allergy,
Asthma and Immunology (AAAAI) guideline [18]. Patients
aged two to five years are expected to achieve this antibody
level to 50% or more of the immunizing serotypes, and patients
six years or older should achieve this target antibody level to
70% or more of the immunizing serotypes tested [19,20].
2.4. Other laboratory tests
Serum immunoglobulins and IgG subclasses were measured
on a BNII nephelometer (Dade Behring, UK). Age related
normal ranges were applied. Specific antibodies to tetanus
toxoid and Hib were measured by commercial ELISA (Binding
Site, UK). All laboratory tests of immune function were carried
out in accordance with the test manufacturers' protocols in
diagnostic immunology laboratories that were accredited by
Clinical Pathology Accreditation (CPA) UK. Microbiological
testing was performed by the Department of Microbiology,
University Hospitals of Leicester NHS Trust, following
guidelines issued by the CF Trust [21]. Pseudomonas status
was defined in line with Lee et al. [22].
2.5. Statistical analysis
All data were entered into a secure Excel database (Microsoft,
Redmond, WA) and analysed using GraphPad (version 3.02;
GraphPad Software Inc., La Jolla, CA) or Stata Statistical
Software (release 11, 2009; StataCorp LP, TX). Descriptive
statistics were used to describe cystic fibrosis patients and results
of immunological and microbiological tests. Geometric means
(with 95% confidence intervals) were calculated for serotype-
specific pneumococcal polysaccharide antibody levels. Mann–
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levels in non-vaccinated individuals and those vaccinated with
either Prevenar or Pneumovax II. Chi-square tests were used to
compare numbers of serotype-specific antibody levels achieving
the protective threshold level between groups of patients
receiving the different pneumococcal vaccines. Differences in
demographic data between groups were analysed using the
Mann–Whitney U test, and the data were expressed as medians
with ranges. Univariate and multivariate statistical analyses with
logistic regression were used to explore the association between
children with impaired antibody responses to Pneumovax II
immunization and established parameters of cystic fibrosis
disease severity (FEV1% predicted, Northern score, S–K score,
BMI-z score and Pseudomonas status). Clinical variables were
controlled for age as a confounder in the multivariate model, and
coefficients, with their 95% confidence intervals, were calculat-
ed. Cross-validation of logistic regressionmodels was undertaken
by calculating the Akaike Information Criterion (AIC), and the
model with the lowest AIC was chosen as the best predictive
model.
3. Results
3.1. Serotype-specific pneumococcal antibody levels and
responses to vaccination
All children with cystic fibrosis undergoing annual review in
the qualifying 12 month period were recruited to the study, and
their data were analysed (n = 52). In 6 patients, no sample was
received for estimation of pneumococcal antibodies. Baseline
pneumococcal antibody levels were therefore available for 46
children with CF who completed their annual review during the
study period. Nine of these children (age range 1–3 years; 3
males and 6 females) had been immunized with the conjugated
vaccine Prevenar 7 as part of the routine childhood vaccination
programme. Mean serotype-specific antibody levels in these
children were greater than the putative protective level against
invasive infection (0.35 mg/L) for all 7 immunizing serotypes
(Table 1 and Fig. 1a), in spite of the blood tests being obtained
up to 2 years after completion of the primary vaccination
regime. In contrast, in 37 children who had not previously been
immunized against pneumococcus (age range 4–18 years; 17
males and 20 females), mean serotype-specific antibody levelsTable 1
Serotype-specific pneumococcal antibody levels (mg/L) in non-vaccinated patients a
Serotype Non-vaccinated (n = 37) Prevenar 7 (n = 9)
4 0.05 (0.03–0.09) 2.01 (1.26–3.22) ***
6B 0.12 (0.07–0.20) 8.02 (5.33–12.06) **
9V 0.10 (0.06–0.18) 2.40 (1.35–4.28) ***
14 0.10 (0.05–0.17) 3.72 (1.51–9.17) ***
18C 0.14 (0.07–0.26) 4.10 (2.2–7.65) ***
19F 0.13 (0.07–0.23) 6.83 (4.21–11.08) **
23F 0.11 (0.07–0.16) 3.66 (1.78–7.49) ***
Serotype-specific pneumococcal antibody levels are given in mg/L, for the seven
instances where antibody levels exceeded the upper limit of detection of the assay, t
95% confidence interval). Statistical significance of differences between antibody
Pneumovax II, and between post-vaccination levels following Prevenar 7 or Pneumwere non-protective (b0.35 mg/L) for all serotypes tested
(Table 1), indicating low levels of natural immunity.
Based on the baseline pneumococcal antibody levels, thirty
three (of the 37) patients who had not been previously immunized
(age range 4–17 years; 18 males and 15 females) received a
single dose of the unconjugated pneumococcal polysaccharide
vaccine, Pneumovax II, and had post-immunization antibody
responses measured 4–6 weeks following the immunization.
Only 7 patients (21%) generated protective (N0.35 mg/L)
serotype-specific antibody levels to all 7 serotypes contained in
both Pneumovax II and Prevenar 7 (Fig. 1a), and mean
serotype-specific antibody levels were lower for all 7 serotypes
in patients recently immunized with Pneumovax II than in
patients who had been immunized with Prevenar 7 (Table 1).
In view of the relatively poor antibody responses to
immunization with Pneumovax II, we wished to see whether
there was a relationship between bacterial polysaccharide vaccine
responses and disease severity. Using criteria based on an
international guideline for evaluating antibody responses follow-
ing pneumococcal polysaccharide vaccination [18], we stratified
patients into those with normal antibody responses and those with
impaired antibody responses to the immunization. Only seven of
the 33 children (21%) immunized with Pneumovax II mounted
normal antibody responses to the immunization. Twenty six
patients (79%) failed to achieve the post-immunization target
antibody thresholds, and were considered to have impaired
antibody responses to the vaccination (Fig. 1b and Supplemen-
tary Table 1). The data suggest that impaired antibody responses
to immunization with unconjugated pneumococcal polysaccha-
ride antigens were common in children with CF, which was not
seen when the polysaccharide antigens were conjugated to a
protein carrier.
3.2. Impaired antibody responses and disease severity
Demographic details of the patients with normal antibody
responses to immunization with Pneumovax II and those with
impaired antibody responses to the immunization are given in
Table 2. Patients with impaired antibody responses tended to be
older than those with normal antibody responses (Table 2 and
Fig. 1c). Childrenmore than 10 years old weremore likely to have
impaired antibody responses to pneumococcal polysaccharide
vaccination than children less than 10 years old (p b 0.05;nd in patients immunized with Prevenar 7 or with Pneumovax II.
Pneumovax II (n = 33) Prevenar vs Pneumovax
0.50 (0.26–0.95) *** *
* 0.54 (0.27–1.08) *** ***
0.41 (0.22–0.78) ** **
1.09 (0.59–2.02) *** ns
0.91 (0.44–1.88) *** ns
* 0.94 (0.48–1.81) *** **
0.46 (0.24–0.88) *** ***
pneumococcal serotypes contained in both Prevenar 7 and Pneumovax II. (In
his value was used in the analysis). Data are presented as geometric mean (with
levels in non-vaccinated patients and those vaccinated with Prevenar 7 or
ovax II is indicated by asterisks (*p b 0.05; **p b 0.01; ***p b 0.001).
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mutation on the antibody response to pneumococcal immuniza-
tion. Details of FEV1% predicted, Northern scores, S–K scores,
BMI-z scores and infection with Pseudomonas are shown in
Table 2. In univariate analysis, there were significant associations
between impaired anti-pneumococcal antibody responses and
more severe S–K and Northern scores, and a trend towards lowera)
b)
c)
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FEV1% predicted (Table 3a). There was no association between
impaired anti-pneumococcal antibody responses and BMI-z score.
As expected, FEV1% predicted, Northern chest radiograph score
and S–K score were significantly correlated with age in our
patients (data not shown). We therefore constructed a multivariate
forward stepwise regression model, in which the association
between impaired anti-pneumococcal antibody responses and S–
K and Northern scores, FEV1% predicted and BMI-z scores was
controlled for age as a confounder. Taking age into account, the
association between impaired antibody response to pneumococcal
vaccination andworse S–K score remained statistically significant
(Table 3b).
3.3. Association of impaired antibody response with
microbiological status
Five of seven children (71%) with normal anti-pneumococcal
antibody responses and twenty three of twenty six children (88%)
with impaired anti-pneumococcal antibody responses had at least
one positive respiratory microbiological pathogen isolated during
the study period. Infections with S. aureus were seen in both
groups of patients. Patients with impaired anti-pneumococcal
antibody responses showed a broader range of respiratory
pathogens, including Aspergillus fumigatus, H. influenzae,
Stenotrophomonas maltiphilia and atypical Mycobacteria, than
patients with normal anti-pneumococcal antibody responses
(Table 4). P. aeruginosa was isolated from the respiratory
secretions of eight patients and Burkholderia cepacia was
isolated from one sample, all from children with impaired
anti-pneumococcal antibody responses. There was only one
positive isolate of S. pneumoniae during the study period, which
was from a patient with an impaired anti-pneumococcal antibody
response.
3.4. Correlation with other immune parameters
There was no correlation between clinical parameters of the
severity of CF disease (FEV1% predicted, Northern score, S–K
score, BMI-z score or Pseudomonas status) and serum
immunoglobulin or IgG subclass levels. Similarly, there was
no significant association between serum IgG, IgA, or IgMFig. 1. (a) Number of individuals with pneumococcal serotype-specific antibody
levels N0.35 mg/L following immunization with Prevenar 7 or Pneumovax II.
Individual patients immunized with either Prevenar 7 or Pneumovax II are
represented by filled circles, with the number of serotype-specific antibody levels
to the seven serotypes contained in both Prevenar 7 and Pneumovax II above the
protective level of 0.35 mg/L displayed on the y-axis. (b) Antibody responses of
children with CF to immunization with Pneumovax II. Data are presented as the
number of pneumococcal serotype-specific antibody responses (from a total of 13
tested) achieving the target level (1.3 mg/L) following immunization with
Pneumovax II; each open circle represents an individual patient with a normal
antibody response to the immunization, whilst filled circles represent individual
patients with impaired antibody responses to the immunization, as defined in the
Methods; p b 0.0001 byMann–WhitneyU test. (c) Relationship between patient age
and antibody response to immunization with Pneumovax II in children with CF. The
number of patients with normal (open bars) or impaired (hatched bars) antibody
responses to pneumococcal polysaccharide immunization was stratified into 3 age
groups; b6 years old, 6–10 years, and N10 years.
Table 2
Demographic and clinical data on patients with normal antibody responses and those with impaired antibody responses to pneumococcal polysaccharide (Pneumovax
II) immunization.
Clinical parameters Normal responders (n = 7) Patients with impaired antibody responses (n = 26)
Age (years) 6.9 (5–15) a 10.9 (4–17) a
Sex (M:F) 4:3 14:12
Genotype (n)
DF508/DF508 3 14
DF508/other 4 9
Other/other 0 3
FEV1 (% predicted) 105 (102–119) a 93 (56–119) a
Northern score 0 (0–2) a 2 (0–7) a
S–K score 100 (90–100) a 90 (70–100) a
BMI-z score 0.18 (−0.91–+0.93) a −0.07 (−2.18–+1.51) a
Pseudomonas b
Never 7 (100%) 18 (69%)
Intermittent 0 5 (19%)
Chronic infection 0 3 (12%)
a Data presented as median (with range).
b Pseudomonas status was defined in line with UK CF Trust guidelines.21,22 Chronic infection was defined as N50% of the preceding 12 months being
Pseudomonas aeruginosa positive, intermittent infection if less than 50% of the time, and ‘never’ if no growth in the preceding 12 months.
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immunization. However, there was a significant association
between an impaired pneumococcal antibody response and a
low IgG2 subclass level (Table 3a).
4. Discussion
This is the first study to report antibody responses to
pneumococcal immunization in children with CF. We found that
children with CF with no history of pneumococcal immunization
had low (non-protective) levels of serotype-specific anti-
pneumococcal antibodies for all pneumococcal serotypes tested.
This is in contrast with a previous report, which concluded that the
majority of CF patients with no history of pneumococcalTable 3
(a) Univariate and (b) multivariate (after adjusting for patient age) analysis of
clinical and immunological parameters as predictors of impaired antibody
responses to pneumococcal polysaccharide antigens.
Predictors of impaired anti-pneumococcal antibody responses
Patient 95% confidence interval
Characteristic Coefficient Lower Upper p value
(a)
Sex 0.13 −1.55 1.82 0.88
Age (years) 0.29 −0.01 0.59 0.06
FEV1% predicted −0.10 −0.20 0.004 0.06
S–K score −0.27 −0.47 −0.06 0.01 ⁎
Northern score 1.03 0.10 1.95 0.03 ⁎
BMI-z score 0.18 −0.33 0.68 0.50
IgG2 1.44 0.01 2.86 0.05 ⁎
(b)
FEV1% predicted −10.92 −25.75 3.92 0.14
S–K score −10.02 −17.49 −2.54 0.01 ⁎
Northern score 1.21 −0.21 2.63 0.09
BMI-z score −0.11 −0.93 0.71 0.71
⁎ Statistically significant associations are highlighted.vaccination had protective anti-pneumococcal antibody levels
[23]. The difference in the findings may be explained by the lower
antibody threshold used to indicate protection (0.2 mg/L), and by
the inclusion of adults, in their study [23]. All of 9 children
immunized with Prevenar 7 in our study had protective antibody
levels (N0.35 mg/L) to all 7 serotypes contained in the vaccine.
The introduction of universal immunization of children with a
conjugated pneumococcal vaccine is likely, therefore, to have a
significant impact on anti-pneumococcal antibody levels in
children with CF. In contrast, immunization with Pneumovax II
induced protective immunity to the seven serotypes contained in
both Prevenar 7 and Pneumovax II in only 21% of patients and
failed to induce protective immunity to any of these serotypes in 3
(9%) of the patients immunized.
A key finding of our study was that a high proportion (over
75%) of children with CF aged 4 years or older in our cohort
failed to make normal antibody responses to the unconjugated
polysaccharide vaccine, Pneumovax II. Taking age into account,
these patients had significantly lower S–K scores than the patients
who mounted normal antibody responses to the immunization. In
addition, patients with impaired anti-pneumococcal polysaccha-
ride antibody responses showed a higher prevalence of positive
microbiological isolates generally, and all infections with
P. aeruginosa occurred in this group. These data suggest that
impaired antibody responses to bacterial polysaccharide antigens
in children with CF are common and may be associated with
greater severity of lung disease and increased isolation of
important respiratory pathogens from sputum. Furthermore, they
raise questions about the efficacy of Pneumovax II immunization
in children with CF. It is of note that our CF patients with impaired
antibody responses to Pneumovax II were older than those with
normal antibody responses to the immunization, as antibody
responses to polysaccharide antigens generally improve through-
out childhood [19,20,24].
Impaired polysaccharide antibody responses in patients with
CF have been reported previously, in relation to natural antibody
Table 4
Microbiological isolates in patients with normal vs impaired anti-pneumococcal antibody responses during the 12 month study period.
Organism Patients with normal pneumococcal
antibody responses a (n = 7)
Patients with impaired pneumococcal
antibody responses a (n = 26)
Staphylococcus aureus 5 (71%) 12 (46%)
Aspergillus fumigatus 1 (14%) 11 (42%)
Pseudomonas sp. 0 8 (31%)
Haemophilus influenzae 0 7 (27%)
Stenotrophomonas maltiphilia 0 3 (12%)
Moraxella catarrhalis 0 2 (8%)
Group A β-haemolytic Streptococcus 0 2 (8%)
Atypical Mycobacteria b 0 2 (8%)
Methicillin-resistant Staphylococcus aureus 0 1 (4%)
Burkholderia cepacia 0 1 (4%)
Streptococcus pneumoniae 0 1 (4%)
a Numbers of patients in each group with a specific organism isolated during the study period, regardless of the number of occasions on which the organism was
isolated).
b Mycobacterium chelonae x1; Mycobacterium goodii x1.
637M.J. Browning et al. / Journal of Cystic Fibrosis 13 (2014) 632–638levels to the Hib polyribophosphate (PRP) antigen and
P. aeruginosa lipopolysaccharide [25]. In addition,
hypogammaglobulinaemia G has been reported, mainly in
younger children with CF, although this was associated with
milder lung disease compared to age-matched CF children with
normal or high IgG levels [9,10]. Similarly, IgG subclass
deficiency has been reported in children with CF, with no clear
association with disease severity [11,12]. Of the immune
parameters that we studied, only impaired anti-pneumococcal
antibody responses correlated with parameters of CF disease
severity. We found reduced serum levels of IgG and IgG
subclasses in a proportion of our patients, but these did not
correlate with disease severity. We did not determine the GM or
KM immunoglobulin allotypes of our patients, although these
have been shown to influence antibody responses to polysaccha-
ride antigens [25,26].
The effect of pneumococcal immunization on long-term
clinical outcomes in children with CF has, to our knowledge,
not been studied. Whether adequate pneumococcal antibody
levels translate into reductions of respiratory exacerbations or
improved clinical outcomes can only be answered with an
adequately powered, multicentre, randomized controlled trial.
However, the deficient antibody responses to pneumococcal
polysaccharide antigens observed in our patients may be
indicative of a broader deficiency in the humoral immune
response to bacterial polysaccharide antigens [18,25], potentially
predisposing to infection with a range of bacteria that produce
extracellular polysaccharides, including both mucoid and
non-mucoid strains of P. aeruginosa [25,27]. Thus, impaired
polysaccharide antibody responses may be of particular relevance
in patients with CF.
Our study is limited by its retrospective nature, and the
relatively small number of patients. We did not recruit a local
cohort of age-matched healthy children immunized with
Pneumovax II. However, the criteria that we used to assess the
adequacy of response to pneumococcal immunization are based
on an international expert guideline [18] and are supported by
data from immunization of more than 1000 healthy children
[19,20]. The validity of these criteria was confirmed in two recentstudies, in healthy Finnish children (with a similar age profile to
our cohort) and in healthy Mexican children (aged 4 years or
older), immunized with Pneumovax II [24,28]. Furthermore,
Dransfield et al. reported that Pneumovax II induced mean
serotype-specific pneumococcal antibody levels N1.3 mg/L to 6
of 7 serotypes tested, albeit in adult patients with COPD [29].
Taken together, these results suggest a difference in the way that
pneumococcal polysaccharide antigens are handled in children
with CF compared with healthy children or adults with other
chronic airways disease and that this may have implications for
disease progression in CF patients.
In conclusion, our results show that immunization with the
conjugated pneumococcal vaccine, Prevenar 7, was more
effective in establishing protective immunity against pneumo-
coccal disease than immunization with Pneumovax II in
children with CF. Based on our data, we now recommend
immunization with Prevenar (13) rather than Pneumovax II in
children with CF with non-protective pneumococcal antibody
levels. Furthermore, impaired antibody responses to (unconju-
gated) pneumococcal polysaccharide vaccination were com-
mon in our cohort of children with cystic fibrosis and were
associated with worse clinical scores and a higher incidence of
Pseudomonas infection. The finding of impaired antibody
responses to pneumococcal polysaccharide vaccination in
children with CF was unexpected, and investigation of the
underlying reasons for this merits further study.
Declarations
The authors declare that there are no conflicts of interest in
publishing the data.
The results have not been published previously.
Funding for the research was from Departmental Research
Funds.
Acknowledgments
MJB was involved in study design, data analysis and
interpretation and co-wrote the manuscript. MTCL and PK
638 M.J. Browning et al. / Journal of Cystic Fibrosis 13 (2014) 632–638were involved in data extraction and were involved in the writing
of the manuscript. RD, GB-M and DK performed the estimation
of the pneumococcal antibody levels and critically reviewed the
manuscript. MW and MV performed statistical analysis and
wrote the statistics section. COC was involved in designing the
study and drafting of the manuscript. EAG was involved in study
design, and research conduct and co-ordination, and co-wrote the
final manuscript. EAG is also the guarantor for the content of the
manuscript. All authors approved submission of the manuscript.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2014.02.002.
References
[1] Rowe SM, Miller S, Sorscher EJ. Mechanisms of disease: cystic fibrosis.
N Engl J Med 2005;352(19):1992–2001.
[2] O'Malley CA. Infection control in cystic fibrosis: cohorting, cross-
contamination, and the respiratory therapist. Respir Care 2009;54(5):641–57.
[3] Smyth A. Update on treatment of pulmonary exacerbations in cystic fibrosis.
Curr Opin Pulm Med 2006;12(6):440–4.
[4] Browning Michael J, Lim Michael TC, Kenia Priti, Whittle Michelle,
Doffinger Rainer, Barcenas-Morales Gabriela, et al. Population structure,
antimicrobial resistance, and mutation frequencies of Streptococcus
pneumoniae isolates from cystic fibrosis patients. J Clin Microbiol
2005;43(5):2207–14.
[5] Malfroot A, AdamG, Ciofu O, Doring G, Knoop C, Lang AB, et al. European
Cystic Fibrosis Society Vaccination Group. Immunisation in the current
management of cystic fibrosis patients. J Cyst Fibros 2005;4(2):77–87.
[6] American Academy of Pediatrics. Pneumococcal infections. In: Pickering
LK, editor. Red Book: Report of the Committee on Infectious Diseases.
Elk Grove Village, IL: American Academy of Pediatrics; 2009. p. 524–35.
[7] Health Protection Agency. Pneumococcal vaccination recommendations—
who should be vaccinated?; 2011.
[8] Burgess L, Southern KW. Pneumococcal vaccines for cystic fibrosis.
Cochrane Database Syst Rev 2012 Sep 12;9:CD008865.
[9] Matthews Jr WJ, Williams M, Oliphint B, Geha R, Colten HR.
Hypogammaglobulinemia in patients with cystic fibrosis. N Engl J
Med 1980;302(5):245–9.
[10] Wheeler WB, Williams M, Matthews Jr WJ, Colten HR. Progression of
cystic fibrosis lung disease as a function of serum immunoglobulin G
levels: a 5-year longitudinal study. J Pediatr 1984;104(5):695–9.
[11] Garside JP, Kerrin DP, Brownlee KG, Gooi HC, Taylor JM, Conway SP.
Immunoglobulin and IgG subclass levels in a regional pediatric cystic
fibrosis clinic. Pediatr Pulmonol 2005;39(2):135–40.
[12] Garside JP, Kerrin DP, Brownlee KG, Gooi HC, Taylor JM, Conway SP.
Low gammaglobulin subclass 2 levels in paediatric cystic fibrosis patients
followed over a 2-year period. Pediatr Pulmonol 2007;42(2):125–30.
[13] Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R,
et al. Interpretative strategies for lung function tests. Eur Respir J
2005;26(5):948–68.[14] Conway SP, Pond MN, Bowler I, Smith DL, Simmonds EJ, Joanes DN,
et al. The chest radiograph in cystic fibrosis: a new scoring system
compared with the Chrispin-Norman and Brasfield scores. Thorax
1994;49(9):860–2.
[15] Doershuk CF, Matthews LW, Tucker AS, Nudleman H, Eddy G, Wise M,
et al. A 5 year clinical evaluation of a therapeutic program for patients
with cystic fibrosis. J Pediatr 1964;65:677–93.
[16] Willcocks LC, Chaudhry AN, Smith JC, Ojha S, Doffinger R, Watson CJ,
et al. The effect of sirolimus therapy on vaccine responses in transplant
recipients. Am J Transplant 2007;7(8):2006–11.
[17] Siber GR, Chang I, Baker S, Fernsten P, O'Brien KL, Santosham M, et al.
Estimating the protective concentration of anti-pneumococcal capsular
polysaccharide antibodies. Vaccine 2007;25(19):3816–26.
[18] Orange JS, Ballow M, Stiehm ER, Ballas ZK, Chinen J, de la Morena M,
et al. Use and interpretation of diagnostic vaccination in primary
immunodeficiency: a working group report of the basic and clinical
immunology interest section of the American Academy of Allergy, Asthma
and Immunology. J Allergy Clin Immunol 2012;130:S1–S24.
[19] Sorensen RU, Leiva LE, Javier III FC, Sacerdote DM, Bradford N, Butler
B, et al. Influence of age on the response to Streptococcus pneumoniae
vaccine in patients with recurrent infections and normal immunoglobulin
concentrations. J Allergy Clin Immunol 1998;102(2):215–21.
[20] Paris K, Sorensen RU. Assessment and clinical interpretation of polysaccharide
antibody responses. Ann Allergy Asthma Immunol 2007;99(5):462–4.
[21] Laboratory standards for processing microbiological samples from people
with cystic fibrosis. UK CF Trust 2010. www.cysticfibrosis.org.uk/media/
82034/CD_Laboratory_Standards_Sep_10.pdf.
[22] Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM.
Evaluation of a new definition for chronic Pseudomonas aeruginosa
infection in cystic fibrosis patients. J Cyst Fibros 2003;2(1):29–34.
[23] Lahiri T, Waltz DA. Preimmunization anti-pneumococcal antibody levels
are protective in a majority of patients with cystic fibrosis. Pediatrics
2001;108(4):E62.
[24] Ruuskanen O, Nurkka A, Helminen M, Viljanen MK, Kayty H,
Kainulainen L. Specific antibody deficiency in children with recurrent
respiratory infections: a controlled study with follow up. Clin Exp
Immunol 2013;172(2):238–44.
[25] Moss RB, Hsu YP, van Eede PH, van Leeuwen AM, Lewiston NJ, de Lange
G. Altered antibody isotype in cystic fibrosis: impaired natural antibody
response to polysaccharide antigens. Pediatr Res 1987;22(6):708–13.
[26] Poland GA, Jacobson RM. The genetic basis for variation in antibody
response to vaccines. Curr Opin Pediatr 1998;10(2):208–15.
[27] Mishra M, Byrd MS, Sergeant S, Azad AK, Parsek MR, McPhail L, et al.
Pseudomonas aeruginosa PsI polysaccharide reduces neutrophil phagocy-
tosis and the oxidative response by limiting complement-mediated
opsonization. Cell Microbiol 2012;14(1):95–106.
[28] Espinosa-Padilla SE, Murata C, Estrada-Parra S, Santos-Argumedo L,
Mascarenas C, Franco-Paredes C, et al. Immunogenicity of a 23-valent
pneumococcal polysaccharide vaccine among Mexican Children. Arch
Med Res 2012;43(5):402–5.
[29] Dransfield MT, Harnden S, Burton RL, Albert RK, Bailey WC, Casaburi
R, et al. Long-term comparative immunogenicity of protein conjugate and
free polysaccharide pneumococcal vaccines in chronic obstructive
pulmonary disease. Clin Infect Dis 2012;55(5):e35–44.
